Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparative study of bowel cleanliness and side effects of low-dose CleanViewAL powder vs ORA-FANG tablet
KCT0006143Phase 4Completed
- Sponsor
- Taejoon Pharmaceutical Co., Ltd.
- Start
- Feb 2021
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Non-biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4 trial of CleanViewAL and Orafang in functional bowel disorder (FBD) and colonic polyp (2 arms), sponsored by Taejoon Pharmaceutical Co., Ltd. Primary endpoints: Bowel cleanliness and Side effects. Started Feb 2021; status: completed.
02
Drugs
CleanViewALOrafang
03
Conditions
functional bowel disorder (FBD)colonic polyp
Beyond the preview
Go deeper on KCT0006143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0006143.